Pharma News

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Novel formulation for cost-effective and thermo-stable Insulin
    19 October 2021

    Novel formulation for cost-effective and thermo-stable Insulin

    Availability of injectable insulin formulation has been a major breakthrough in diabetes management. However, insulin needs to be kept in a refrigerator, which, otherwise after some hours becomes unfit for use due to fibrillation (some kind of ‘solidification’). Its prolonged storage even in normal refrigerator is also not good. Therefore, its thermal instability and fibrillation at non-refrigerated temperatures demands storage and maintenance of cold chain, making it expensive.

  • 19 October 2021
    Dr. Reddys Laboratories announces approval for Lenalidomide Capsules from the USFDA

    Dr. Reddys Laboratories Ltd announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules, from the U.S. Food and Drug Administration (USFDA). With this approval, Dr. Reddy’s is eligible for 180 days of generic drug exclusivity for Lenalidomide Capsules, 2.5 mg and 20 mg.

  • 12 October 2021
    Covaxin get emergency approval for children aged 2-18 years

    The Subject Expert Committee (SEC) of CDSCO has granted emergency use approval (EUA) to Covaxin for children in the 2-18 years age group. Covaxin is developed by Hyderabad based Bharat Biotech.

    Caovaxin had completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age in September and submitted the trial data to the Drugs Controller General of India (DCGI) at the start of this month.

  • 11 October 2021
    Sandoz acquire cephalosporin business of GSK

     Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotics business.

    Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum)) in more than 100 markets, further reinforcing its leading global position in antibiotics. In 2020, the three brands had combined sales of approximately USD 140 million in the relevant markets.

  • 11 October 2021
    OSE Immunotherapeutics receives European patent for Tedopi, cancer vaccine

    OSE Immunotherapeutics SA announced that it has received notice of allowance from the European Patent Office for a patent application related to Tedopi®, a neoepitope therapeutic vaccine, protecting a method for manufacturing a ready-to-use peptide emulsion for its use in the treatment of cancers in HLA-A2 positive patients. This patent will provide a protection until 2038.

  • 11 October 2021
    BRUKINSA approved for treatment of Patients with Mantle Cell Lymphoma

    BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) has been approved in Australia for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

  • 6 October 2021
    Manganese makes its mark in drug synthesis

    Rice chemist Julian West and graduate student Yen-Chu Lu found that an Earth-abundant salt of manganese further simplifies the process of synthesizing fluoroketones, precursor molecules for drug design and manufacture.

    The complex method required catalysts of expensive silver until the West lab figured out how to replace it with a cerium-based compound. That in turn led the researchers to eye manganese as a next-level catalyst.

  • 6 October 2021
    Cancer chemotherapy drug reverses Alzheimer symptoms in mice

    A drug commonly used to treat cancer can restore memory and cognitive function in mice that display symptoms of Alzheimer’s disease, new UBC research has found.

  • 2 October 2021
    Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals

    Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd announced a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II). Hunter syndrome is caused by a deficiency of IDS and manifests in different forms.

  • 2 October 2021
    Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK

    Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021.

    The decision is based on the clinical trial data generated to date, most notably the previously reported results from the INTR@PID Lung 037 study, which did not replicate the encouraging data observed in earlier studies. Based on the data generated during the agreement, no milestone payments were made by GSK and no future milestone obligations remain.

Subscribe to Pharma News